Sanofi Acquires Dynavax for $15.50 per Share, 39% Premium

Dynavax Technologies Corp's stock surged by 39.62% in pre-market trading, reaching a 52-week high, following the announcement of its acquisition by Sanofi.

The acquisition agreement involves Sanofi acquiring Dynavax for $15.50 per share, totaling approximately $2.2 billion, which significantly enhances Sanofi's market position in adult immunization. This strategic move integrates Dynavax's marketed adult hepatitis B vaccine HEPLISAV-B and a promising shingles vaccine candidate into Sanofi's portfolio, addressing significant unmet public health needs and expanding its market share. The deal is expected to close in the first quarter of 2026, reflecting Sanofi's commitment to the future vaccine market.

This acquisition not only boosts Dynavax's stock price but also positions Sanofi to better meet the health needs of nearly 100 million unvaccinated adults in the U.S., indicating a strong strategic investment in the adult immunization sector.